You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Amgen Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for Amgen Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amgen Inc CORLANOR ivabradine SOLUTION;ORAL 209964-001 Apr 22, 2019 RX Yes Yes 7,361,649 ⤷  Sign Up Y Y ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No 10,092,541*PED ⤷  Sign Up Y ⤷  Sign Up
Amgen Inc LUMAKRAS sotorasib TABLET;ORAL 214665-003 Jun 26, 2024 RX Yes No 10,519,146 ⤷  Sign Up Y Y ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 AB RX Yes No 7,427,638*PED ⤷  Sign Up Y ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Amgen Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 9,724,330 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 7,659,302 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 6,020,358 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 6,962,940 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 7,893,101 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 7,208,516 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for AMGEN INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg, 20 mg and30 mg ➤ Subscribe 2018-03-22

Supplementary Protection Certificates for Amgen Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2962690 122019000070 Germany ⤷  Sign Up PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115
2962690 LUC00125 Luxembourg ⤷  Sign Up PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116
2962690 C201930044 Spain ⤷  Sign Up PRODUCT NAME: APREMILAST O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/14/981; DATE OF AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/981; DATE OF FIRST AUTHORISATION IN EEA: 20150115
2962690 CR 2019 00033 Denmark ⤷  Sign Up PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116
2962690 37/2019 Austria ⤷  Sign Up PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 (MITTEILUNG) 20150116
2962690 1990037-2 Sweden ⤷  Sign Up PRODUCT NAME: APREMILAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/981 20150116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.